vs
AMREP CORP.（AXR）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
AMREP CORP.的季度营收约是Protalix BioTherapeutics, Inc.的1.6倍（$14.6M vs $9.1M），AMREP CORP.净利率更高（21.6% vs -60.3%，领先81.9%），AMREP CORP.同比增速更快（93.8% vs -49.9%），AMREP CORP.自由现金流更多（$5.4M vs $1.6M），过去两年Protalix BioTherapeutics, Inc.的营收复合增速更高（-6.7% vs -13.6%）
AMREP是一家总部位于美国新泽西州普林斯顿的企业，核心业务涵盖房地产与媒体服务领域。公司前身为美国地产石油公司，于1961年正式成立，在相关行业拥有六十余年的发展运营历史。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
AXR vs PLX — 直观对比
营收规模更大
AXR
是对方的1.6倍
$9.1M
营收增速更快
AXR
高出143.7%
-49.9%
净利率更高
AXR
高出81.9%
-60.3%
自由现金流更多
AXR
多$3.8M
$1.6M
两年增速更快
PLX
近两年复合增速
-13.6%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $14.6M | $9.1M |
| 净利润 | $3.1M | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | 20.6% | -51.1% |
| 净利率 | 21.6% | -60.3% |
| 营收同比 | 93.8% | -49.9% |
| 净利润同比 | 338.9% | -184.8% |
| 每股收益（稀释后） | $0.58 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXRPLX
| Q1 26 | $14.6M | — | ||
| Q4 25 | $9.4M | $9.1M | ||
| Q3 25 | $17.9M | $17.9M | ||
| Q2 25 | $11.2M | $15.7M | ||
| Q1 25 | $7.5M | $10.1M | ||
| Q4 24 | $11.9M | $18.2M | ||
| Q3 24 | $19.1M | $18.0M | ||
| Q2 24 | $19.5M | $13.5M |
净利润AXRPLX
| Q1 26 | $3.1M | — | ||
| Q4 25 | $1.2M | $-5.5M | ||
| Q3 25 | $4.7M | $2.4M | ||
| Q2 25 | $3.9M | $164.0K | ||
| Q1 25 | $717.0K | $-3.6M | ||
| Q4 24 | $4.0M | $6.5M | ||
| Q3 24 | $4.1M | $3.2M | ||
| Q2 24 | $4.1M | $-2.2M |
毛利率AXRPLX
| Q1 26 | — | — | ||
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% |
营业利润率AXRPLX
| Q1 26 | 20.6% | — | ||
| Q4 25 | 11.9% | -51.1% | ||
| Q3 25 | 34.4% | 11.9% | ||
| Q2 25 | 31.7% | 7.5% | ||
| Q1 25 | 5.7% | -41.0% | ||
| Q4 24 | 26.4% | 39.6% | ||
| Q3 24 | 26.1% | 22.2% | ||
| Q2 24 | 23.9% | -18.0% |
净利率AXRPLX
| Q1 26 | 21.6% | — | ||
| Q4 25 | 12.8% | -60.3% | ||
| Q3 25 | 26.3% | 13.2% | ||
| Q2 25 | 34.8% | 1.0% | ||
| Q1 25 | 9.5% | -35.8% | ||
| Q4 24 | 33.9% | 35.6% | ||
| Q3 24 | 21.3% | 18.0% | ||
| Q2 24 | 21.2% | -16.4% |
每股收益（稀释后）AXRPLX
| Q1 26 | $0.58 | — | ||
| Q4 25 | $0.22 | $-0.06 | ||
| Q3 25 | $0.87 | $0.03 | ||
| Q2 25 | $0.73 | $0.00 | ||
| Q1 25 | $0.13 | $-0.05 | ||
| Q4 24 | $0.75 | $0.10 | ||
| Q3 24 | $0.76 | $0.03 | ||
| Q2 24 | $0.77 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $50.0M | $14.7M |
| 总债务越低越好 | $21.0K | — |
| 股东权益账面价值 | $139.4M | $48.2M |
| 总资产 | $143.9M | $82.3M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资AXRPLX
| Q1 26 | $50.0M | — | ||
| Q4 25 | $44.6M | $14.7M | ||
| Q3 25 | $48.9M | $13.6M | ||
| Q2 25 | $39.5M | $17.9M | ||
| Q1 25 | $36.9M | $19.5M | ||
| Q4 24 | $40.1M | $19.8M | ||
| Q3 24 | $40.4M | $27.4M | ||
| Q2 24 | $29.7M | $23.4M |
总债务AXRPLX
| Q1 26 | $21.0K | — | ||
| Q4 25 | $23.0K | — | ||
| Q3 25 | $25.0K | — | ||
| Q2 25 | $26.0K | — | ||
| Q1 25 | $29.0K | — | ||
| Q4 24 | $32.0K | — | ||
| Q3 24 | $34.0K | — | ||
| Q2 24 | $35.0K | — |
股东权益AXRPLX
| Q1 26 | $139.4M | — | ||
| Q4 25 | $136.0M | $48.2M | ||
| Q3 25 | $134.7M | $52.9M | ||
| Q2 25 | $130.0M | $49.9M | ||
| Q1 25 | $126.0M | $45.2M | ||
| Q4 24 | $125.1M | $43.2M | ||
| Q3 24 | $122.2M | $32.4M | ||
| Q2 24 | $118.0M | $28.6M |
总资产AXRPLX
| Q1 26 | $143.9M | — | ||
| Q4 25 | $140.1M | $82.3M | ||
| Q3 25 | $140.7M | $82.3M | ||
| Q2 25 | $133.8M | $78.5M | ||
| Q1 25 | $128.9M | $73.9M | ||
| Q4 24 | $129.1M | $73.4M | ||
| Q3 24 | $127.0M | $61.6M | ||
| Q2 24 | $122.8M | $91.5M |
负债/权益比AXRPLX
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.4M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $5.4M | $1.6M |
| 自由现金流率自由现金流/营收 | 37.0% | 17.8% |
| 资本支出强度资本支出/营收 | 0.1% | 4.4% |
| 现金转化率经营现金流/净利润 | 1.72× | — |
| 过去12个月自由现金流最近4个季度 | $20.2M | $-13.6M |
8季度趋势，按日历期对齐
经营现金流AXRPLX
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | $2.0M | ||
| Q3 25 | $9.5M | $-3.7M | ||
| Q2 25 | $10.2M | $-5.2M | ||
| Q1 25 | $-3.2M | $-5.1M | ||
| Q4 24 | $-182.0K | $4.0M | ||
| Q3 24 | $10.7M | $4.1M | ||
| Q2 24 | $10.7M | $-3.6M |
自由现金流AXRPLX
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | $1.6M | ||
| Q3 25 | $9.5M | $-4.2M | ||
| Q2 25 | $9.7M | $-5.7M | ||
| Q1 25 | $-3.3M | $-5.4M | ||
| Q4 24 | $-268.0K | $3.6M | ||
| Q3 24 | $10.7M | $4.0M | ||
| Q2 24 | $10.3M | $-3.8M |
自由现金流率AXRPLX
| Q1 26 | 37.0% | — | ||
| Q4 25 | -45.9% | 17.8% | ||
| Q3 25 | 53.2% | -23.7% | ||
| Q2 25 | 86.4% | -36.2% | ||
| Q1 25 | -43.4% | -53.0% | ||
| Q4 24 | -2.3% | 19.6% | ||
| Q3 24 | 55.8% | 22.4% | ||
| Q2 24 | 52.5% | -28.1% |
资本支出强度AXRPLX
| Q1 26 | 0.1% | — | ||
| Q4 25 | 0.6% | 4.4% | ||
| Q3 25 | 0.1% | 2.8% | ||
| Q2 25 | 5.2% | 2.8% | ||
| Q1 25 | 0.3% | 3.0% | ||
| Q4 24 | 0.7% | 2.3% | ||
| Q3 24 | 0.2% | 0.5% | ||
| Q2 24 | 2.3% | 1.3% |
现金转化率AXRPLX
| Q1 26 | 1.72× | — | ||
| Q4 25 | -3.54× | — | ||
| Q3 25 | 2.03× | -1.58× | ||
| Q2 25 | 2.63× | -31.91× | ||
| Q1 25 | -4.51× | — | ||
| Q4 24 | -0.05× | 0.61× | ||
| Q3 24 | 2.63× | 1.27× | ||
| Q2 24 | 2.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXR
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
